Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery

Christoph Varenhorst, Ulrica Alström, Benjamin M. Scirica, Charles W. Hogue, Nils Åsenblad, Robert F. Storey, Ph Gabriel Steg, Jay Horrow, Kenneth W. Mahaffey, Richard C. Becker, Stefan James, Christopher P. Cannon, Gunnar Brandrup-Wognsen, Lars Wallentin, Claes Held

Research output: Contribution to journalArticle

Abstract

Objectives: This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Background: In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality. Methods: In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death. Results: Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p <0.05, and bleeding: 27 vs. 9, p <0.01, for clopidogrel and ticagrelor, respectively). Conclusions: The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872)

Original languageEnglish (US)
Pages (from-to)1623-1630
Number of pages8
JournalJournal of the American College of Cardiology
Volume60
Issue number17
DOIs
StatePublished - Oct 23 2012

Fingerprint

clopidogrel
Coronary Artery Bypass
Mortality
Hemorrhage
Transplants
Infection
Blood Vessels
Blood Platelets
Cardiovascular Infections
Sudden Death
Ticagrelor
Cardiac Arrhythmias
Cause of Death
Heart Failure
Stroke
Myocardial Infarction

Keywords

  • bypass
  • clopidogrel
  • myocardial infarction
  • surgery
  • ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. / Varenhorst, Christoph; Alström, Ulrica; Scirica, Benjamin M.; Hogue, Charles W.; Åsenblad, Nils; Storey, Robert F.; Steg, Ph Gabriel; Horrow, Jay; Mahaffey, Kenneth W.; Becker, Richard C.; James, Stefan; Cannon, Christopher P.; Brandrup-Wognsen, Gunnar; Wallentin, Lars; Held, Claes.

In: Journal of the American College of Cardiology, Vol. 60, No. 17, 23.10.2012, p. 1623-1630.

Research output: Contribution to journalArticle

Varenhorst, C, Alström, U, Scirica, BM, Hogue, CW, Åsenblad, N, Storey, RF, Steg, PG, Horrow, J, Mahaffey, KW, Becker, RC, James, S, Cannon, CP, Brandrup-Wognsen, G, Wallentin, L & Held, C 2012, 'Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery', Journal of the American College of Cardiology, vol. 60, no. 17, pp. 1623-1630. https://doi.org/10.1016/j.jacc.2012.07.021
Varenhorst, Christoph ; Alström, Ulrica ; Scirica, Benjamin M. ; Hogue, Charles W. ; Åsenblad, Nils ; Storey, Robert F. ; Steg, Ph Gabriel ; Horrow, Jay ; Mahaffey, Kenneth W. ; Becker, Richard C. ; James, Stefan ; Cannon, Christopher P. ; Brandrup-Wognsen, Gunnar ; Wallentin, Lars ; Held, Claes. / Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. In: Journal of the American College of Cardiology. 2012 ; Vol. 60, No. 17. pp. 1623-1630.
@article{41b4888fcc6945c59e3967cb8a538637,
title = "Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery",
abstract = "Objectives: This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Background: In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality. Methods: In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death. Results: Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p <0.05, and bleeding: 27 vs. 9, p <0.01, for clopidogrel and ticagrelor, respectively). Conclusions: The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872)",
keywords = "bypass, clopidogrel, myocardial infarction, surgery, ticagrelor",
author = "Christoph Varenhorst and Ulrica Alstr{\"o}m and Scirica, {Benjamin M.} and Hogue, {Charles W.} and Nils {\AA}senblad and Storey, {Robert F.} and Steg, {Ph Gabriel} and Jay Horrow and Mahaffey, {Kenneth W.} and Becker, {Richard C.} and Stefan James and Cannon, {Christopher P.} and Gunnar Brandrup-Wognsen and Lars Wallentin and Claes Held",
year = "2012",
month = "10",
day = "23",
doi = "10.1016/j.jacc.2012.07.021",
language = "English (US)",
volume = "60",
pages = "1623--1630",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery

AU - Varenhorst, Christoph

AU - Alström, Ulrica

AU - Scirica, Benjamin M.

AU - Hogue, Charles W.

AU - Åsenblad, Nils

AU - Storey, Robert F.

AU - Steg, Ph Gabriel

AU - Horrow, Jay

AU - Mahaffey, Kenneth W.

AU - Becker, Richard C.

AU - James, Stefan

AU - Cannon, Christopher P.

AU - Brandrup-Wognsen, Gunnar

AU - Wallentin, Lars

AU - Held, Claes

PY - 2012/10/23

Y1 - 2012/10/23

N2 - Objectives: This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Background: In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality. Methods: In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death. Results: Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p <0.05, and bleeding: 27 vs. 9, p <0.01, for clopidogrel and ticagrelor, respectively). Conclusions: The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872)

AB - Objectives: This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Background: In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality. Methods: In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death. Results: Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p <0.05, and bleeding: 27 vs. 9, p <0.01, for clopidogrel and ticagrelor, respectively). Conclusions: The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872)

KW - bypass

KW - clopidogrel

KW - myocardial infarction

KW - surgery

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84867582405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867582405&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2012.07.021

DO - 10.1016/j.jacc.2012.07.021

M3 - Article

C2 - 23021325

AN - SCOPUS:84867582405

VL - 60

SP - 1623

EP - 1630

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -